H.C. Wainwright Reiterates Buy Rating on Tracon Pharmaceuticals (TCON) Following Positive IDMC Review of ENVASARC Trial
Tweet Send to a Friend
H.C. Wainwright analyst Ed White reiterated a Buy rating and $12.00 price target on Tracon Pharmaceuticals (NASDAQ: TCON) following positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
